{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:20:30Z","timestamp":1788193230828,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100030775","name":"Bharati Vidyapeeth","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.virol.2026.111007","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:16:24Z","timestamp":1781453784000},"page":"111007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of MPLA and chimeric TLR agonist adjuvants in RSV virus-like particle vaccines delivered by the intramuscular route"],"prefix":"10.1016","volume":"623","author":[{"given":"Ahmedali S.","family":"Mandviwala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Liman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke L.W.","family":"Huckriede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh Chandra","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshad P.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.virol.2026.111007_bib1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1128\/CVI.00609-15","article-title":"Brief history and characterization of enhanced respiratory syncytial virus disease","volume":"23","author":"Acosta","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"issue":"2","key":"10.1016\/j.virol.2026.111007_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/pathogens14020104","article-title":"Preventing RSV infection in children: current passive immunizations and vaccine development","volume":"14","author":"Babawale","year":"2025","journal-title":"Pathogens"},{"key":"10.1016\/j.virol.2026.111007_bib3","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/14760584.2025.2508517","article-title":"Virus-like particles: a versatile and effective vaccine platform","author":"Bachmann","year":"2025","journal-title":"Expert Review of Vaccines [Internet]"},{"issue":"104","key":"10.1016\/j.virol.2026.111007_bib4","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1126\/sciimmunol.ado5937","article-title":"Linking vaccine adjuvant mechanisms of action to function","volume":"10","author":"Ben-Akiva","year":"2025","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.virol.2026.111007_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.938598","article-title":"Intramuscular inoculation of AS02-Adjuvanted respiratory syncytial virus (RSV) F subunit vaccine shows better efficiency and safety than subcutaneous inoculation in BALB\/c mice","volume":"13","author":"Bian","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.virol.2026.111007_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-024-00912-1","article-title":"Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine","volume":"9","author":"Bissett","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.virol.2026.111007_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04216-6","article-title":"Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model","volume":"9","author":"Blanco","year":"2018","journal-title":"Nat. Commun."},{"issue":"41","key":"10.1016\/j.virol.2026.111007_bib7","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1016\/j.vaccine.2015.08.071","article-title":"Maternal transfer of RSV immunity in cotton rats vaccinated during pregnancy","volume":"33","author":"Blanco","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2026.111007_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040206618770518","article-title":"Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus","volume":"26","author":"Boukhvalova","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"issue":"1","key":"10.1016\/j.virol.2026.111007_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41541-023-00729-4","article-title":"Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models","volume":"8","author":"Bouzya","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"2","key":"10.1016\/j.virol.2026.111007_bib11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/v15020392","article-title":"Respiratory viruses and virus-like particle vaccine development: how far have we advanced?","volume":"15","author":"Chu","year":"2023","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.virol.2026.111007_bib12","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3390\/vaccines9121504","article-title":"Innovations in the insect cell expression system for industrial recombinant vaccine antigen production","volume":"9","author":"Cox","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"10.1016\/j.virol.2026.111007_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.168110","article-title":"Human T cells efficiently control RSV infection","volume":"8","author":"De","year":"2023","journal-title":"JCI Insight"},{"issue":"13\u201314","key":"10.1016\/j.virol.2026.111007_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.drudis.2011.04.006","article-title":"Particulate vaccines: on the quest for optimal delivery and immune response","volume":"16","author":"De Temmerman","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.virol.2026.111007_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103352","article-title":"Global outbreaks of respiratory syncytial virus infections from 1960 to 2025: a systematic review and meta-analysis","volume":"86","author":"Duan","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.virol.2026.111007_bib16","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3389\/fimmu.2020.01673","article-title":"Prefusion RSV F immunization elicits Th2-Mediated lung pathology in mice when formulated with a Th2 (but not a Th1\/Th2-Balanced) adjuvant despite complete viral protection","volume":"11","author":"Eichinger","year":"2020","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.virol.2026.111007_bib17","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jix503","article-title":"An adjuvanted, postfusion F protein\u2013based vaccine did not prevent respiratory syncytial virus illness in older adults","volume":"216","author":"Falloon","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.virol.2026.111007_bib18","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1473-3099(24)00226-3","article-title":"Long-term efficacy and immunogenicity of Ad26.RSV.preF\u2013RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study","volume":"24","author":"Falsey","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.virol.2026.111007_bib19","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4161\/hv.27908","article-title":"Cell-mediated immune responses to respiratory syncytial virus infection: Magnitude, kinetics, and correlates with morbidity and age","volume":"10","author":"Geevarghese","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"issue":"9","key":"10.1016\/j.virol.2026.111007_bib20","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.4049\/jimmunol.172.9.5269","article-title":"IgG2a-Mediated enhancement of antibody and T cell responses and its relation to inhibitory and activating Fc\u03b3 receptors","volume":"172","author":"Getahun","year":"2004","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.virol.2026.111007_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005035","article-title":"Characterization of a prefusion-specific antibody that recognizes a Quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein","volume":"11","author":"Gilman","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2026.111007_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2024.100867","article-title":"RSV immunisation in infants: weighing the options","volume":"38","author":"G\u00fcnther","year":"2024","journal-title":"The Lancet Regional Health - Europe"},{"issue":"9","key":"10.1016\/j.virol.2026.111007_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/v12090906","article-title":"Two RSV platforms for G, F, or G+F proteins VLPs","volume":"12","author":"Ha","year":"2020","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.virol.2026.111007_bib24","article-title":"Immune responses and protection profiles in mice induced by subunit vaccine candidates based on the extracellular domain antigen of respiratory syncytial virus G protein combined with different adjuvants","volume":"12","author":"Han","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"23","key":"10.1016\/j.virol.2026.111007_bib25","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.vaccine.2017.04.053","article-title":"A multi-laboratory study of diverse RSV neutralization assays indicates feasibility for harmonization with an international standard","volume":"35","author":"Hosken","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2026.111007_bib26","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04886596. 2025. Efficacy Study of Gsk's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above. ClinicalTrials.gov. NCT04886596."},{"issue":"1","key":"10.1016\/j.virol.2026.111007_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13036-025-00562-4","article-title":"Insect cell expression system: advances in applications, engineering strategies, and bioprocess development","volume":"19","author":"Huang","year":"2025","journal-title":"J. Biol. Eng."},{"issue":"6","key":"10.1016\/j.virol.2026.111007_bib29","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/cid\/ciae010","article-title":"Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons","volume":"78","author":"Ison","year":"2024","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.virol.2026.111007_bib30","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/irv.12112","article-title":"A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats","volume":"7","author":"Kamphuis","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"issue":"4","key":"10.1016\/j.virol.2026.111007_bib31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2026.111007_bib32","article-title":"The recent landscape of RSV vaccine research","volume":"13","author":"Kelleher","year":"2025","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"4","key":"10.1016\/j.virol.2026.111007_bib33","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.virol.2026.111007_bib34","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3390\/vaccines11030695","article-title":"The integrated consideration of vaccine platforms, adjuvants, and delivery routes for successful vaccine development","volume":"11","author":"Kozak","year":"2023","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.virol.2026.111007_bib36","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3390\/pharmaceutics15030782","article-title":"Virus-like particle vaccine expressing the respiratory syncytial virus pre-fusion and G proteins confers protection against RSV challenge infection","volume":"15","author":"Lee","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.virol.2026.111007_bib35","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.2147\/IDR.S426039","article-title":"Virus-like particles assembled using respiratory syncytial virus matrix protein elicit protective immunity in mice","volume":"16","author":"Lee","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.virol.2026.111007_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1054005","article-title":"Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice","volume":"13","author":"Luo","year":"2022","journal-title":"Front. Immunol."},{"issue":"October","key":"10.1016\/j.virol.2026.111007_bib38","article-title":"Mucosal delivery of a prefusogenic-F, glycoprotein, and matrix proteins-based virus-like particle respiratory syncytial virus vaccine induces protective immunity as evidenced by challenge studies in mice","volume":"598","author":"Mandviwala","year":"2024","journal-title":"Virology"},{"key":"10.1016\/j.virol.2026.111007_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1561297","article-title":"Evaluation of dual pathogen recognition receptor agonists as adjuvants for respiratory syncytial virus - virus-like particles for pulmonary delivery","volume":"16","author":"Mandviwala","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2026.111007_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127203","article-title":"Immunogenicity evaluation of respiratory syncytial virus prefusogenic-F based virus-like-particles consisting of G and M proteins in mice","volume":"56","author":"Mandviwala","year":"2025","journal-title":"Vaccine"},{"issue":"6136","key":"10.1016\/j.virol.2026.111007_bib41","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"issue":"Suppl. ment_2","key":"10.1016\/j.virol.2026.111007_bib42","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1093\/jpids\/piae049","article-title":"RSV prevention within reach for older infants and toddlers: the role of active immunization","volume":"13","author":"Mejias","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"5","key":"10.1016\/j.virol.2026.111007_bib43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/QCO.0000000000000952","article-title":"The disease burden of respiratory syncytial virus in infants","volume":"36","author":"Munro","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"Suppl. ment_2","key":"10.1016\/j.virol.2026.111007_bib44","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1093\/jpids\/piae027","article-title":"A historical perspective on respiratory syncytial virus prevention: a journey spanning over half a century from the setback of an inactive vaccine candidate to the success of passive immunization strategy","volume":"13","author":"Noor","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"12","key":"10.1016\/j.virol.2026.111007_bib45","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1016\/j.celrep.2020.02.111","article-title":"Route of vaccine administration alters antigen trafficking but not innate or adaptive immunity","volume":"30","author":"Ols","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.virol.2026.111007_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.745016","article-title":"Exploration of pattern recognition receptor agonists as candidate adjuvants","volume":"11","author":"Ong","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.virol.2026.111007_bib47","series-title":"Key Roles of Adjuvants in Modern Vaccines","author":"Orr","year":"2013"},{"issue":"41","key":"10.1016\/j.virol.2026.111007_bib48","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.1016\/j.vaccine.2019.07.089","article-title":"Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: structure, antigenic profile, immunogenicity, and protection","volume":"37","author":"Patel","year":"2019","journal-title":"Vaccine"},{"issue":"616","key":"10.1016\/j.virol.2026.111007_bib49","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.1126\/scitranslmed.abj7843","article-title":"Fatal enhanced respiratory syncytial virus disease in toddlers","volume":"13","author":"Polack","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.virol.2026.111007_bib50","article-title":"Challenges and limitations of current RSV prevention strategies in infants and young children: a narrative review","volume":"13","author":"Principi","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.virol.2026.111007_bib51","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/infdis\/jir474","article-title":"Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice","volume":"204","author":"Quan","year":"2011","journal-title":"JID (J. Infect. Dis.)"},{"issue":"33","key":"10.1016\/j.virol.2026.111007_bib52","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1016\/j.vaccine.2021.06.016","article-title":"RSV neutralization assays \u2013 use in immune response assessment","volume":"39","author":"Raghunandan","year":"2021","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.virol.2026.111007_bib53","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.virol.2026.111007_bib54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1128\/CMR.00090-16","article-title":"The human immune response to respiratory syncytial virus infection","volume":"30","author":"Russell","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"issue":"6","key":"10.1016\/j.virol.2026.111007_bib55","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/vaccines13060556","article-title":"The bioengineering of insect cell lines for biotherapeutics and vaccine production: an updated review","volume":"13","author":"Su\u0142ek","year":"2025","journal-title":"Vaccines"},{"issue":"January","key":"10.1016\/j.virol.2026.111007_bib56","article-title":"Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases","volume":"12","author":"Tariq","year":"2022","journal-title":"Front. Microbiol."},{"issue":"24","key":"10.1016\/j.virol.2026.111007_bib57","first-page":"1","article-title":"The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access","volume":"3099","author":"Terstappen","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"MAR","key":"10.1016\/j.virol.2026.111007_bib58","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3389\/fimmu.2019.00548","article-title":"Fc-Mediated antibody effector functions during respiratory syncytial virus infection and disease","volume":"10","author":"van Erp","year":"2019","journal-title":"Front. Immunol."},{"issue":"Suppl. l","key":"10.1016\/j.virol.2026.111007_bib59","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jip.2011.05.004","article-title":"Large-scale production and purification of VLP-Based vaccines","volume":"107","author":"Vicente","year":"2011","journal-title":"J. Invertebr. Pathol."},{"issue":"3","key":"10.1016\/j.virol.2026.111007_bib60","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/CVI.00590-15","article-title":"Mucosal IgG levels correlate better with respiratory syncytial virus load and inflammation than plasma IgG levels","volume":"23","author":"Vissers","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"issue":"5","key":"10.1016\/j.virol.2026.111007_bib61","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1128\/jvi.70.5.2852-2860.1996","article-title":"Respiratory synctial virus infection in BALB\/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern","volume":"70","author":"Waris","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2026.111007_bib62","article-title":"RSV vaccine development: advances and fusion protein-focused strategies","volume":"17","author":"Xu","year":"2026","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.virol.2026.111007_bib63","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3390\/vaccines13111133","article-title":"RSV vaccines: targeting prefusion F and G proteins from structural design to clinical application","volume":"13","author":"Yu","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.virol.2026.111007_bib64","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.virol.2026.111007_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.526965","article-title":"Respiratory syncytial virus F subunit vaccine with AS02 adjuvant elicits balanced, robust humoral and cellular immunity in BALB\/c mice","volume":"11","author":"Zheng","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.virol.2026.111007_bib66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.chom.2021.11.006","article-title":"Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman Primates","volume":"30","author":"Zohar","year":"2022","journal-title":"Cell Host Microbe"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682226002229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682226002229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:04:53Z","timestamp":1788192293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682226002229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":65,"alternative-id":["S0042682226002229"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2026.111007","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of MPLA and chimeric TLR agonist adjuvants in RSV virus-like particle vaccines delivered by the intramuscular route","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2026.111007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111007"}}